376 related articles for article (PubMed ID: 29052905)
1. Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
Mitsuzuka K; Arai Y
Int J Urol; 2018 Jan; 25(1):45-53. PubMed ID: 29052905
[TBL] [Abstract][Full Text] [Related]
2. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer.
Torimoto K; Samma S; Kagebayashi Y; Chihara Y; Tanaka N; Hirayama A; Fujimoto K; Hirao Y
Jpn J Clin Oncol; 2011 Apr; 41(4):577-81. PubMed ID: 21297122
[TBL] [Abstract][Full Text] [Related]
3. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.
Gardner JR; Livingston PM; Fraser SF
J Clin Oncol; 2014 Feb; 32(4):335-46. PubMed ID: 24344218
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
Aragon-Ching JB
J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
[No Abstract] [Full Text] [Related]
5. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risks of androgen deprivation therapy.
Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
[TBL] [Abstract][Full Text] [Related]
7. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
[TBL] [Abstract][Full Text] [Related]
8. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
9. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
10. Management of the side effects of androgen deprivation therapy in men with prostate cancer.
Flaig TW; Glodé LM
Expert Opin Pharmacother; 2008 Nov; 9(16):2829-41. PubMed ID: 18937615
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.
Tzortzis V; Samarinas M; Zachos I; Oeconomou A; Pisters LL; Bargiota A
Hormones (Athens); 2017 Apr; 16(2):115-123. PubMed ID: 28742500
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
15. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
Couderc AL; Villani P; Berbis J; Nouguerède E; Rey D; Rossi D; Lechevallier É; Badinand D; Bastide C; Karsenty G; Boissier R; Amichi K; Muracciole X
BMC Cancer; 2022 Jan; 22(1):78. PubMed ID: 35042460
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
17. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies.
Cheung AS; Zajac JD; Grossmann M
Endocr Relat Cancer; 2014 Oct; 21(5):R371-94. PubMed ID: 25056176
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
Freedland SJ; Eastham J; Shore N
Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
[TBL] [Abstract][Full Text] [Related]
19. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
[TBL] [Abstract][Full Text] [Related]
20. Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.
Tsai HT; Pfeiffer RM; Philips GK; Barac A; Fu AZ; Penson DF; Zhou Y; Potosky AL
J Urol; 2017 May; 197(5):1251-1257. PubMed ID: 27993663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
